Insights

Acquisition Ally Post acquisition by Stryker, Cerus Endovascular gains access to a larger distribution and customer base in the neurovascular market, presenting cross-sell opportunities for Stryker’s broader product portfolio and potential integration with Stryker Neurovascular channels.

Growth Potential Revenue is in the low single digits with recent FDA clearance activity and ongoing product development, signaling room for aggressive sales motion to expand adoption of their intra-saccular devices among neurointerventional centers and hospitals.

Strategic Fit Target customers include hospitals and specialty centers focusing on intracranial aneurysm treatment; align outreach with neurointerventionalists and procurement teams to position Cerus products as complementary to existing Stryker neurovascular offerings.

Product Pipeline Historical milestones show FDA clearance and new microcatheters; emphasize opportunities in expanding product adoption, trials, and clinical study engagements to drive wider usage and credentialed outcomes in neurointervention programs.

Finance Signals Small but growing funding history and a strategically valuable asset within a larger medical device ecosystem; leverage Stryker-backed resources and investor interest to secure commitments for pilot programs and early access deals with key neurovascular centers.

Similar companies to Cerus Endovascular

Cerus Endovascular Tech Stack

Cerus Endovascular uses 7 technology products and services including Webpack, DreamWeaver, Google Fonts API, and more. Explore Cerus Endovascular's tech stack below.

  • Webpack
    Development
  • DreamWeaver
    Editors
  • Google Fonts API
    Font Scripts
  • React
    Javascript Frameworks
  • RequireJS
    Javascript Frameworks
  • TweenMax
    Javascript Frameworks
  • Zepto
    Javascript Libraries

Media & News

Cerus Endovascular's Email Address Formats

Cerus Endovascular uses at least 1 email format:
Cerus Endovascular Email FormatsExamplePercentage
First.Last@cerusendo.comJohn.Doe@cerusendo.com
100%

Frequently Asked Questions

What is Cerus Endovascular's official website and social media links?

Minus sign iconPlus sign icon
Cerus Endovascular's official website is cerusendo.com and has social profiles on LinkedIn.

How much revenue does Cerus Endovascular generate?

Minus sign iconPlus sign icon
As of November 2026, Cerus Endovascular's annual revenue is estimated to be $1M - $10M.

What is Cerus Endovascular's NAICS code?

Minus sign iconPlus sign icon
Cerus Endovascular's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Cerus Endovascular have currently?

Minus sign iconPlus sign icon
As of November 2026, Cerus Endovascular has approximately 13 employees across 2 continents, including North America and Europe. Key team members include Creative Director: G. C. and Senior Manager Regulatory Affairs: A. L. Explore Cerus Endovascular's employee directory with LeadIQ.

What industry does Cerus Endovascular belong to?

Minus sign iconPlus sign icon
Cerus Endovascular operates in the Medical Equipment Manufacturing industry.

What technology does Cerus Endovascular use?

Minus sign iconPlus sign icon
Cerus Endovascular's tech stack includes Webpack, DreamWeaver, Google Fonts API, React, RequireJS, TweenMax and Zepto.

What is Cerus Endovascular's email format?

Minus sign iconPlus sign icon
Cerus Endovascular's email format typically follows the pattern of First.Last@cerusendo.com. Find more Cerus Endovascular email formats with LeadIQ.

How much funding has Cerus Endovascular raised to date?

Minus sign iconPlus sign icon
As of November 2026, Cerus Endovascular has raised $2.3M in funding. The last funding round occurred on Feb 21, 2020.

When was Cerus Endovascular founded?

Minus sign iconPlus sign icon
Cerus Endovascular was founded in 2014.
Cerus Endovascular logo

Cerus Endovascular

Medical Equipment ManufacturingCalifornia, United States11-50 Employees

Cerus Endovascular designs and manufactures intra-saccular neurointerventional devices intended for the treatment of intracranial aneurysms. The company operates in the medical equipment manufacturing industry, building specialized tools and systems for interventional neuroradiology procedures. It is based in Fremont, California, and is a relatively small to mid-sized organization.

Its products target clinicians and hospitals performing neurovascular procedures, addressing the challenges of treating complex intracranial aneurysms. In May 2023, Stryker completed the acquisition of Cerus Endovascular. Earlier, in 2022, the company announced FDA 510(k) clearance for its 027 microcatheters, marking a regulatory milestone.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2014
Employees
11-50

Section iconFunding & Financials

  • $2.3M

    Cerus Endovascular has raised a total of $2.3M of funding over 2 rounds. Their latest funding round was raised on Feb 21, 2020 as a Series B.

  • $1M - $10M

    Cerus Endovascular's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.